The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …

AL amyloidosis patients are difficult to diagnose. Patients having multi-organ and particularly
cardiac involvement are considered to have bad prognosis. Early diagnosis is therefore …

Systemic amyloidosis is a rare disease that is rarely cured. Systemic immunoglobulin light-
chain amyloidosis (AL) is the most common type, usually the result of monoclonal light …

Systemic amyloid light-chain (AL) amyloidosis is a protein conformation disorder caused by
clonal plasma cell dyscrasias. Symptoms result from fibrillar extracellular deposits in various …

Amyloidosis is a rare and threatening condition that may require intensive care because of
amyloid deposit‐related organ dysfunction or therapy‐related adverse events. Although new …

OBJECTIVES: The prognosis for light chain amyloidosis (AL) is generally poor, particularly
with cardiac, renal and multi-organ involvement. Treatment options for patients with …

Abstract 1858 Systemic light chain amyloidosis (AL amyloidosis) is a condition where clonal
plasma cells produce misfolded insoluble immunoglobulin light chains that deposit in …

Introduction: Systemic light-chain (AL) amyloidosis is an infiltrative disorder associated with
an underlying plasma cells dyscrasia, in which monoclonal immunoglobulin light chains …

Shen and coworkers elegantly validated a composite hematologic and organ response
(CHOR) model in 388 patients with light chain (AL) amyloidosis treated between 2008 and …

The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data
have shown promising results for several novel agents. We review the management of AL …